Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2010 Sep;36(3):695-6; author reply 696-8.
doi: 10.1183/09031936.00071710.

Pirfenidone in idiopathic pulmonary fibrosis

J Swigris, D Fairclough
Comment

Pirfenidone in idiopathic pulmonary fibrosis

J Swigris et al. Eur Respir J. 2010 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Statement of Interest: A statement of interest for J. Swigris can be found at www.erj.ersjournals.com/misc/statements.dtl

Figures

Figure 1
Figure 1
Mean value of outcome of interest for subjects whose last study visit occurred at 16 (group 1), 8 (group 2) or 4 weeks (group 3). BL: baseline.
See this image and copyright information in PMC

Comment on

  • Pirfenidone in idiopathic pulmonary fibrosis.
    Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Taniguchi H, et al. Eur Respir J. 2010 Apr;35(4):821-9. doi: 10.1183/09031936.00005209. Epub 2009 Dec 8. Eur Respir J. 2010. PMID: 19996196 Clinical Trial.

References

    1. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821–829. - PubMed
    1. Collard HR. Idiopathic pulmonary fibrosis and pirfenidone. Eur Respir J. 2010;35:728–729. - PubMed
    1. Fairclough D. Design and Analysis of Quality of Life Studies in Clinical Trials. 2nd. New York: CRC Press; 2010.

MeSH terms

LinkOut - more resources